# Comparison Of 4 CP-690,550 Doses Vs. Placebo, Each Combined With Methotrexate, For The Treatment Of Rheumatoid Arthritis in Japan

> **NCT00603512** · PHASE2 · COMPLETED · sponsor: **Pfizer** · enrollment: 140 (actual)

## Conditions studied

- Arthritis, Rheumatoid

## Interventions

- **DRUG:** Placebo
- **DRUG:** CP-690,550
- **DRUG:** CP-690,550
- **DRUG:** CP-690,550
- **DRUG:** CP-690,550

## Key facts

- **NCT ID:** NCT00603512
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-01
- **Primary completion:** 2008-09
- **Final completion:** 2008-09
- **Target enrollment:** 140 (ACTUAL)
- **Last updated:** 2013-01-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00603512

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00603512, "Comparison Of 4 CP-690,550 Doses Vs. Placebo, Each Combined With Methotrexate, For The Treatment Of Rheumatoid Arthritis in Japan". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00603512. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*